Member Info for roger65

Wow roger56, such scintillating and ingenious wit. Your dinner parties must be a thrill to attend.

Perhaps I should start something. Seems the current BODs are even more hapless than the former CEO. A long wait for that commodity bull run the CEOs appear to be keeping their fingers crossed for...

Agreed Starres ie years away.

Jlc - sorry but I received an email response from the NOMAD saying the specific funding sums to be received by GDR will only be announced in an RNS ‘if deemed significant and therefore market sensitive…’

If the NOMAD is spreading ‘false rumours’ then things here are worse than we thought. Get over yourself. You’ve picked a dud and no amount of ostrich impersonation will help you or anyone invested until there’s a new CEO who knows how to deliver commercialisation off GDR products.

Sorry Ben, watched your video. And the point of it is what, exactly?

Come on Shed, give it up. Directors have had their fun here and shed loads of money from pis for many years and delivered absolutely zero. They are never going to because EUZ is a sham. Lifestyle company. Laurence Read left firmly believing EUZ had had its day even two years ago and yet myles is still there taking a monthly salary for what?

Please DO NOT invest in this rubbish. You will only lose money and waste time reading posts like the one below from Shed, carefully constructed to give the impression something is just around the corner. It has been like this for 5 years now and still nothing good has happened but the posts remain ever full of anticipation. Just beware.

Hey apps: another quick question if you don’t mind….

If an announcement lands and the share goes into suspension, is there a specified time limit by which the proposed RTO must happen? Or can it just stay suspended indefinitely?

If an RNS landed tomorrow saying license transferred and money now in KOD bank accounts what do people expect from the sp? Is 1p feasible?

And now £466k. BODs prudent?? Hmmm

Hmmm r we appear to be dropping further and heading for the.6s again.

Can this company put something together to attract investors? Rick Rule coming on board hasn’t had the effect I’d hoped…yet. More patience required

I imagine the pressure is really building from RF for Budd to deliver some news. He’s actually managed nothing at all since end of March. We were told about DEvOTE funding but then in an email from the NOMAD they said there would only be an announcement IF the funding was ‘deemed significant’. That suggests to me they’re aware the funding might be negligible. Nothing on FDA. Roll out now has AIHL being used routinely in just 3 hospitals and ‘hope’ it will be more soon. That means sales revenue will be negligible too. CYP2C19 evaluation by NICE delayed twice - it was meant to have been done in July! GDR is now on a knife edge and simply praying for something positive to happen. All the possible positive bits of news are out of BUdd’s control.

On balance even the rampiest posters have to admit things have gone disastrously since end of March. The company is now in the grip of a death spiral finance agreement and having to consider spending $2m on whether or not to pursue the US market with AIHL. It’s in a dire position now imho and I can see the sp dropping further. Hopefully not as low as back to 8p but I think 10p is definitely a possibility by the end of August. Squeaky bum time for many now.

News might not come at anytime on multiple fronts this month

Apologies, you're right Starres. I got AIHL mixed up with CYP2C19. It's the latter that Genomadix are already able to sell. Whether or not they have an established market already I don't know but they are certainly years ahead of GDR with this particular test in the US.

No reason to think GDR won't achieve FDA approval but given its track record with them there's certainly no guarantee either. Plus there's the minor issue of where GDR will get $2m in order to submit an application. And don't forget it will be $2m for AIHL and another $2m for CYP2C19. If they do decide to go for it then there will almost certainly have to be a lot more dilution courtesy of at least another raise if not two, one for each application.

Filter me System. I care not one jot. I'm trying to reason why GDR is performing so badly and offer opinions. You just endlessly state one of the msgs below based on which way the wind is blowing on any given day. I'll stick with my MO and you stick with yours. It obviously keeps you happy.

I"m aware there was probably going to be competition but given Genomadix are ALREADY selling their tests in the US to neonatal units all over the country and that it might take another 2 years for GDR to get theirs to market - not to mention the expense of another $2m (that's if GDR go ahead and submit an application for AIHL at the same expense) - I just don't think all those neonatal units will happily switch to GDR tests and form out for their new testing equipment. I think it's naive to think Genomadix won't also improve their product and tests as they go along so whose to say by the time GDR made it to the US market the Genomadix kit wouldn't be as good and as cheap? No, for me it's looking like AIHL and CYP2C19 will be the UK market and hopefully the EU and ME but I'm writing off the US for GDR products. GDR has now spent SO much time and money attempting to make headway their with various products and frankly got nowhere at all that it's hard to justify further expense and effort unless they can be extremely confident they'll gain approval. And let's be honest, they can't be, going on their track record.

System zero - you've probably put more time and thought into that post than any other you've come up with over the last 12 months or so. Well done. Your posts are always informative and you are clearly moving forward.

We're going up today.

We're going down today.

RNS today

RNS tomorrow

RNS soon

etc

So that's the US market off the menu for GDR with the CYP2C19 test. I have a feeling the GDR test is cheaper and superior but if this one is already selling then it's likely by the time GDR have gained approval from FDA that it will be more established and also more affordable so will GDR get to the table too late....

Not sure. AIHL tests cost about £80 each but more pertinent is how much profit is there after the cost of producing it. Have a vague memory of CYP2C19 tests costing a over £100 each though but cd be wrong. The numbers certainly add up and make for exciting reading but the stressful part in being a GDR share holder is knowing there’s a CEO who doesn’t have the requisite skills or experience to put these tests on the shelves in the US or the EU yet. CYP2C19 still needs registration mark to be sold even in the UK before NICE evaluate it in the autumn.

Stress levels reduced for me by selling out once we hit 15p. I’m keeping a very close eye on things though as I definitely see this turning at some point but not yet. Budd has failed to deliver any news since March and liquidity has dropped through the floor compared to the first 3 months of this year and GDR is now at the mercy of a death spiral finance deal. Circs have conspired against Budd - realisation that GDR have not been selected for quick access to sell in the US by FDA (we were going to get by end of July if it was news) and DEVOTE funding info will only be announced if the sums are ‘deemed significant’ - but things can easily change.

Just my view but RF are now covered with this latest 3m shares were the sp to pop anytime soon on sudden good news. More worryingly in the short term they won’t be bothered by the sp dropping further eg c10p because they will then be able to apply for another allotment of shares at that lower price, which they will be able to sell at a later date without having any restrictions on them. They will also at some point want to redeem a vast number of warrants they are entitled to.

I feel GDR will come good eventually, in spite of the CEO rather than because of him, but it’s going to take longer than expected. End of 2024 UK sales of AIHL will hopefully amount to enough to cover half the company annual costs.

One final thing to remind people of is the statement in the March RNS and that is that the company doesn’t currently plan to increase its monthly costs…. Strikes me that this covered then to announce further costs to cover an application to FDA in the US if they have to go the expensive route ie $2m, which imo they now know they have to.

Idle musings.

Jimi, I think they’ll be asking for more than 3m shares in time. This is just the first tranche covering the shortfall from their initial 6.5m shares which they’ve sold but didn’t raise nearly enough to cover £2m.

If they have 3m of these now though it covers them in case the sp suddenly shot up. Imho I think this will do a bit further and they’ll get the next lot in another month.

Oh dear, looking like the ITS balloon is deflating slowly but surely. Not sure we're going to see any more action here unless the new Ds put out a bit of a teaser.

Is that another bounce similar to the one that was supposedly about to happen at midday according to someone here? lol

Aggh really thought we'd seen the last of the .7s

Hopefully SW is busy negotiating to sell off MFC and generate some serious cash for a drilling project or two somewhere with something valuable in the ground.